http://youtu.be/oMT1EBYYSEg Lynparza (olaparib) is an approved cancer treatment for certain types of advanced ovarian cancers associated with defective BRCA genes. In this new cancer education video, oncologist Dr. Stephen Lemon talks about how Lynparza works, which types of ovarian cancer patients it benefits and what types of sides effects patients may experience from the treatment. As a PARP inhibitor, Lynparza is the first drug of its kind to be approved in the US. PARP inhibitors are class of medication that offers promise for treating BRCA related cancers. These drugs block an enzyme used by cells to repair damage to their DNA. For women who do not carry the BRCA mutation, PARP inhibitors may work by keeping cancer cells from repairing themselves once they've been damaged by chemotherapy treatment, while sparing healthy cells. These PARP inhibitors may be very effective for patients with BRCA mutations, as their tumor cells will already have problems repairing DNA and the PARP inhibitors will make this even worse. Lynparza is marketed by AstraZeneca Pharmaceuticals. Dr. Stephen Lemon is a medical oncologist in private practice ans is not associated with AstraZeneca.